Neurothera Labs Inc
C0A
Company Profile
Business description
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
Contact
325 Front Street West
2nd Floor
TorontoONM5V2Y1
CANT: +1 604 833-6820
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.00 | 57.20 | -0.62% |
| CAC 40 | 8,485.64 | 77.37 | 0.92% |
| DAX 40 | 25,612.03 | 151.55 | 0.60% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,897.27 | 11.14 | -0.10% |
| HKSE | 25,725.55 | 133.33 | -0.52% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 65,024.55 | 3,157.12 | 5.10% |
| NZX 50 Index | 13,814.23 | 51.45 | 0.37% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,991.40 | 58.50 | -0.65% |
| SSE Composite Index | 3,841.62 | 36.92 | 0.97% |